131 related articles for article (PubMed ID: 6582678)
1. Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
Lambertenghi-Deliliers G; Pogliani E; Maiolo AT; Pacciarini MA; Polli EE
Tumori; 1983 Dec; 69(6):515-9. PubMed ID: 6582678
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
3. 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Cerri R; Risso M; Damasio E; Rossi E
Cancer; 1985 Apr; 55(7):1452-4. PubMed ID: 3856461
[TBL] [Abstract][Full Text] [Related]
4. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Cortelezzi A; Pogliani E; Ganzina F; Polli EE
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1041-5. PubMed ID: 3478198
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
6. Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine.
Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Pogliani E; Baldini L; Polli E
Cancer; 1984 Jul; 54(2):199-201. PubMed ID: 6586276
[TBL] [Abstract][Full Text] [Related]
7. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
9. Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
Battista R; D'Emilio A; Vespignani M; Pacciarini MA; Dini E
Tumori; 1986 Aug; 72(4):389-93. PubMed ID: 3464125
[TBL] [Abstract][Full Text] [Related]
10. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
[TBL] [Abstract][Full Text] [Related]
11. Oral idarubicin in adult acute leukemia: a preliminary experience.
Lambertenghi-Deliliers G; Pogliani E; Annaloro C; Pacciarini MA; Polli EE
Tumori; 1986 Apr; 72(2):157-61. PubMed ID: 3458337
[TBL] [Abstract][Full Text] [Related]
12. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
13. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
14. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
Carella AM; Santini G; Giordano D; Frassoni F; Martinengo M; Congiu A; Nati S; Risso M; Cerri R; Marmont A
Leuk Res; 1985; 9(5):631. PubMed ID: 3859711
[No Abstract] [Full Text] [Related]
16. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
17. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin in refractory acute leukemia.
Fülle HH; Hellriegel KP
Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
20. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
Sessa C; Tschopp L; Fopp M; Cavalli F
Invest New Drugs; 1985; 3(4):357-9. PubMed ID: 3866755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
